key: cord-0979841-ndk9atoa
authors: Aguilar, Richard B; Hardigan, Patrick; Mayi, Bindu; Sider, Darby; Piotrkowski, Jared; Mehta, Jinesh; Dev, Jenankan; Seijo, Yelenis; Lewis Camargo, Antonio; Andux, Luis; Hagen, Kathleen; Hernandez, Marlow B
title: Current Understanding of COVID-19 Clinical Course and Investigational Treatments
date: 2020-04-24
journal: nan
DOI: 10.1101/2020.04.19.20071548
sha: ee6641ad22ab8609f549a1867da076b43bcfbd76
doc_id: 979841
cord_uid: ndk9atoa

Importance: Currently, there is no unified framework linking disease progression to established viral levels, clinical tests, inflammatory markers, and investigational treatment options. Objective: It may take many weeks or months to establish a standard treatment approach. Given the growing morbidity and mortality with respect to COVID-19, we present a treatment approach based on a thorough review of scholarly articles and clinical reports. Our focus is on staged progression, clinical algorithms, and individualized treatment. Evidence Review: We followed the protocol for a quality review article proposed by Heyn et. al.1 A literature search was conducted to find all relevant studies related to COVID-19. The search was conducted between April 1, 2020 and April 13, 2020 using the following electronic databases: PubMed (1809 to present), Google Scholar (1900 to present), MEDLINE (1946 to present), CINAHL (1937 to present), and Embase (1980 to present). Keywords used included COVID-19, 2019-nCov, SARS-CoV-2, SARS-CoV, and MERS-CoV, with terms such as efficacy, seroconversion, microbiology, pathophysiology, viral levels, inflammation, survivability, and treatment and pharmacology. No language restriction was placed on the search. Reference lists were manually scanned for additional studies. Findings: Of the articles found in the literature search, 70 were selected for inclusion in this study (67 cited in the body of the manuscript and 3 additional unique references in the Figures). The articles represent work from China, Japan, Taiwan, Vietnam, Rwanda, Israel, France, the United Kingdom, the Netherlands, Canada, and the United States. Most of the articles were cohort or case studies, but we also drew upon information found in guidelines from hospitals and clinics instructing their staff on procedures to follow. In addition, we based some decisions on data collected by agencies such as the CDC, FDA, IHME, ISDA, and Worldometer. None of the case studies or cohort studies used a large number of participants. The largest group of participants numbered less than 500 and some case studies had fewer than 30 patients. However, the review of the literature revealed the need for individualized treatment protocols due to the variability of patient clinical presentation and survivability. A number of factors appear to influence mortality: the stage at which the patient first presented for care, pre-existing health conditions, age, and the viral load the patient carried. Conclusion and Relevance: COVID-19 can be divided into three distinct Stages, beginning at the time of infection (Stage I), sometimes progressing to pulmonary involvement (Stage II, with or without hypoxemia) and less frequently to systemic inflammation (Stage III). In addition to modeling the stages of disease progression, we have also created a treatment algorithm which considers age, comorbidities, clinical presentation, and disease progression to suggest drug classes or treatment modalities. This paper presents the first evidence-based recommendations for individualized treatment for COVID-19.

The coronavirus disease 2019 pandemic is raging throughout the globe. In the United States alone, as of April 10, 2020, there were 560,933 cases along with 22, 127 deaths (Centers for Disease Control and Prevention, CDC). 2 A mathematical model created by

The Institute for Health Metrics and Evaluation (IHME) predicts that in the United States, assuming continued full social distancing, the number of new cases will peak in late April, and related deaths will peak by mid-to-late May. 3 This creates a critical and immediate need for medical treatment and resources.

Preliminary data in the US suggests that COVID-19 may be more infectious and lethal than Influenza H1N1. In the general population, current case-fatality rates for COVID-19 are about 3.9%, and infection rates are about 2.5 under normal conditions. 4 To place this in context, Figure 1 provides a comparison of the reproduction rate and case-fatality rates for major respiratory virus pandemics. 5-7 Data strongly emphasizes early intervention to reduce case-fatality and inhibit reproductive rates.

A number of articles have been published on the clinical course and treatment of the disease. 8-10 The majority of patients present with more than one symptom on admission, although the combination of fever, cough, and shortness of breath is rare. Siddiqi and Mehra proposed a staged progression model based on observed clinical courses in published studies. 11 In Stage 1, or the mild phase, the virus multiplies and establishes residence in the host, predominantly in the respiratory tract. In Stage 2, we see that viral multiplication and localized inflammation in the lungs is common. Stage 3 is marked by extra-pulmonary systemic hyperinflammation syndrome. The prognosis and recovery from Stage 3 is generally poor. Rapid . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04. 19.20071548 doi: medRxiv preprint recognition of what stage the patient is in and deployment of appropriate therapy may have the greatest yield.

Common correlates with poorer outcomes include age, hypertension, diabetes, coronary artery disease, chronic lung disease, and malignancies. 12 Research also finds variations in outcomes due to a dysregulated and exuberant immune response. Patients requiring intensive care have significantly higher levels of IL-6, CRP, ferritin, and D-Dimer. An important therapeutic modality may be to downregulate the cytokine storm, particularly in severe illness. 13 The literature also suggest that disease progression can be predicted. During the severe acute respiratory syndrome (SARS) pandemic, a retrospective analysis revealed that 2-

week cumulative case data could help estimate the total case numbers with accuracy -well before the date of the last reported case. 14 As we have found, there is no unified framework linking disease progression to established viral levels, clinical tests, inflammatory markers, and investigational treatment options. Given that it may take many weeks or months to establish a standard treatment approach and there is a growing morbidity and mortality, we present an initial treatment approach based on a thorough review of currently available scholarly articles and clinical reports. Our focus is on staged progression, clinical algorithms, and individualized treatment.

We followed the protocol for a quality review article proposed by Heyn et al. 1 A literature search was conducted to find all relevant studies related to COVID-19. The search was conducted between April 1, 2020 and April 13, 2020 using the following electronic databases:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 24, 2020. Clinicians and patients should understand the staged progression of COVID-19 ( Figure 2 ). As such, we present a treatment algorithm that recommends no treatment for some and specific treatment for others, depending on age, comorbidities, and symptom severity ( Figure 3 ).

Based on our thorough review of the literature, we correlated the disease course to COVID-19 testing, diagnostic options, and treatment strategies (see Figure 2 ). COVID-19 can be divided into three distinct Stages, beginning at the time of infection (Stage I), sometimes progressing to pulmonary involvement (Stage II, with or without hypoxemia) and less frequently to systemic inflammation (Stage III). We also created a treatment algorithm which considers age, comorbidities, clinical presentation, and disease progression to suggest drug classes or treatment modalities (see Figure 3 ). The specific treatments are summarized in Table   1 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04. 19.20071548 doi: medRxiv preprint

Data exists for early identification of cases at high risk of progression to severe COVID-19. One promising model created in China found that patients who developed severe COVID-19 possessed one of the following diseases: hypertension, diabetes, coronary heart disease, chronic respiratory disease, or tuberculosis. The same model cited age and various serological indicators (such as C-reactive protein (CRP), lactate dehydrogenase (LDH), bilirubin, and others) as factors associated with worse outcomes. 65 Additional research confirmed, in a case-control study, that subjects with high Sequential Organ Failure Assessment (SOFA) scores, with age greater than 65, with hypertension, diabetes, and/or coronary heart disease were at greatest risk. 15 Lastly, Research focusing on viral load and survival found that higher initial viral load is independently associated with worse prognosis. 2

The most common presenting symptoms are fever and cough, followed by myalgia and fatigue. Less commonly, patients may present with sputum production, headache, or abdominal symptoms like diarrhea. 26 In terms of disease progression, a case study of the first five patients diagnosed with COVID-19 in Europe points the way to two different clinical evolutions of the disease: 1. Presenting few symptoms, but showing high viral load from the respiratory tract; 2. A two-step disease process, with worsening of symptoms around 10 days of symptom onset in spite of decreased viral load in respiratory samples. In our model we plot the disease progression as a function of infection, survivability, and inflammation ( Figure 2 ). We identify the inflection point where survival decreases as inflammation increasesapproximately day 10 from symptom onset. Support for this is found in research by Chen J, Qi T, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. 31 Their research found that sepsis and ARDS in hospitalized patients starts around day 10 and 11, respectively. They also found temporal changes in inflammatory laboratory markers beginning at day 4 of illness onset. These included temporal changes in D-dimer, IL-6, serum ferritin, high-sensitivity cardiac troponin I, and lactate dehydrogenase. The differences were statistically significant between survivors and nonsurvivors for all time points. Figure 4 provides the percent change between survivors and nonsurvivors from day 4. In addition, Yang et al. 66 found that the patients admitted to the ICU with severe hypoxemia had a 50% probability of survival at day 7 of ICU admission (corresponding to Day ~17 in Figure 2 ).

The incubation period is on average 5 days. In most patients, initial presenting symptoms are mild (though a small number of patients can be asymptomatic throughout the course of the disease). Stage I symptoms include fever, cough, fatigue, and body aches, but, in a minority of cases can include headache, GI symptoms, anosmia, as well as others. Duration of initial symptoms is 5-7 days, correlating with a peak in viral load. 26 During this time, the appropriate diagnostic test is a nasopharyngeal PCR. Laboratory studies may include an elevated D-Dimer and prothrombin time, as well as lymphopenia (see Figure 2 ). Given that symptoms in this stage are mild, and correlated with viremia, the appropriate treatment modality is supportive care or an antiviral. Nevertheless, treatment must be individualized, based on a patient's age, comorbidities, presenting symptoms, and drug interactions (see Figure 3 and Table 1 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. 

Some patients progress into Stage II, which is characterized by a decrease in viral levels and an increase in inflammation that initially localizes to the lungs. Infiltrates are typically seen on chest x-ray (CXR) or computed tomography (CT). Similar to symptom duration in Stage I, the typical symptom course in Stage II is also 5-7 days. Treatment with antivirals is still indicated, but given an average decrease in viral levels during this stage, that treatment is theoretically less effective than in Stage I. Moreover, Stage II is divided into two sub-stages (IIA and IIB), depending on whether a patient is hypoxemic or not. This distinction is important for management (see Figure 2 ). In Stage IIB, the patient is significantly dyspneic and may benefit, depending on age and comorbidities, from the use of corticosteroids or other antiinflammatory treatments (see Figure 3 ).

Although only a minority of patients (estimated at 10-15%) progress to Stage III, mortality within this stage is considerable (estimated at 20-30%). The morbidity and mortality are generally due to uncontrolled inflammation, which at this point is systemic. The most important symptom is respiratory distress (correlating in a typical patient to a Pulse Ox < 92%).

Laboratory markers include significantly increased CRP and IL-6 levels. [66] [67] As in Stage II, treatment may include anti-virals (if the patient is still viremic), but agents to counteract inflammation and its effects (such as microthrombi) must be considered (see Figure 2) . A summary of investigational therapies can be found in Table 1 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04. 19.20071548 doi: medRxiv preprint A number of clinical trials are exploring pre-exposure and post-exposure prophylaxis.

There is no definitive evidence that any particular treatment modality is effective but antivirals, hydroxychloroquine, and convalescent plasma are being proposed. Anti-virals, like Remdesivir, may proof beneficial at any stage of disease. [39] [40] Hydroxychloroquine is postulated to have antiviral properties, and it has been definitively proven as an immunomodulator. 32 Convalescent plasma provides the antibody support needed to envelope and destroy the virus while preventing the exuberant immune response or cytokine release that leads to significant pathology, particularly in Stages IIb and III. 23

This review has several limitations. First, the incredible volume and speed at which data is published about the treatment of COVID-19 indicates that research findings and recommendations may change. Second, the research used to create the review came from small studies, often-times with very few controls. Third, the articles were limited to Englishlanguage publications or translations, so relevant international data could be lacking.

This paper presents the first evidence-based recommendations for individualized treatment for COVID-19. Based upon the observed transmission and mortality rates, health professionals urgently need to align patient baseline risk to disease stage and investigational treatment options. The COVID-19 pandemic represents the greatest public health crisis in three generations; the need for comprehensive management cannot be overstated.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. . 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04. 19.20071548 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04. 19.20071548 doi: medRxiv preprint

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical course and outcomes of critically ill patients with SARS-Co-V-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

The acute respiratory distress syndrome

Effects of chloroquine on viral infections: an old drug against today's diseases?

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized trial

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Medicine and Infectious Disease

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience

Effective treatment of severe COVID-19 patients with tocilizumab

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA

Acute respiratory distress syndrome: The Berlin Definition

Experimental treatment with Favipiravir for COVID-19: an open-label control study

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Clinical features of 69 cases with coronavirus disease

The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

The Ribavirin pregnancy registry: findings after 5 years of enrollment

Macrolide treatment for COVID-19:will this be the way forward? Biosci Trends

Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions

Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. Cardiology Magazine

Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacotherapy

Effects of early corticosteroid treatment on plasma SARSassociated Coronavirus RNA concentrations in adult patients

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China

Brigham and Women's Hospital: COVID-19 Clinical Guidelines

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

Type 1 interferons as a potential treatment against COVID-19

Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome. MedRxiv

Massachusetts General Hospital COVID-19 treatment guidance

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Lilly begins clinical testing of therapies for COVID-19

A tool to early predict severe 2019-novel coronavirus pneumonia (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China. MedRxiv

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Clinical course and outcomes of critically ill patients with SARS-Co-V-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality